An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1
What this study shows
Dropped a bombshell: rapamycin does NOT fully block mTORC1. Using Torin1 (which jams the active site directly), the authors showed rapamycin leaves important mTORC1 jobs running - notably 4E-BP1 phosphorylation and autophagy suppression. This reframed a decade of rapamycin experiments and launched the search for complete inhibitors.
At a glance
| Evidence type | M Molecular — cells, biochemistry, structure Marked M because it is molecular or in-vitro work (model: Mouse/human cells) rather than a whole-organism health-outcome study. That is often exactly where causal biology gets established -- the code says which system the finding was shown in, and nothing about how good the work is. |
| Study type | 5 - Mechanistic / In Vitro |
| Model system | Mouse/human cells |
| Journal | Journal of Biological Chemistry |
| Year | 2009 |
| Peer reviewed | Yes |
| Record last updated | 2026-08-22 |
| Source | DOI 10.1074/jbc.M900301200 · PMID 19150980 · Free full text (PMC2658096) |
Extracted findings
| Intervention | Torin1 (ATP-competitive mTOR inhibitor) |
| Target | mTORC1 (rapamycin-resistant outputs, 4E-BP) |
| Model | Mouse/human cells |
| Effect | Torin1 reveals rapamycin-resistant functions of mTORC1 (e.g. 4E-BP1 phosphorylation, autophagy) |
In the Atlas
Related topics
Open questions that cite this study
- Cited as supporting evidence for the open question mTORC1-selective (mTORC2-sparing) dosing captures longevity without insulin resistance.
Answers that reference this study
- Discussed in the plain-language answer What are mTOR inhibitors? The full list, by mechanism.
- Discussed in the plain-language answer mTORC1 vs mTORC2 – what's the difference?.
More studies on this topic
- mTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation (2015)
- The translational landscape of mTOR signalling steers cancer initiation and metastasis (2012)
- A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer (2023)
- The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial (2025)
Learn the biology
Want to understand the biology behind this study? → How to Read an mTOR Paper